Latest Conference Articles

Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.

A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.

To date, OPTIMISMM is the only phase 3 study in early RRMM to report a significantly and clinically meaningful PFS improvement in LEN-exposed patients.

Prospective genomics can inform subsequent clinical trial analysis aiming at matching outcome with tumor genotyping.

The single-use triple-therapy device has proven significantly more easily managed by patients in a crossover study.

Findings should prompt future investigations into care disparities at skilled-care facilities to mediate higher mortality rates observed among senior survivors of critical illness.

When inhaled, cinnamaldehyde can disrupt the lung's anti-bacterial defense system, exposing users to respiratory infection.

Of the 246 patients who underwent lung resections, 203 patients had a FEV1 less than 0.8.

Increasing particulate matter and ozone rates, even in lower-pollution regions, is putting the elderly at risk of acute respiratory distress syndrome.

The longtime therapy Symbicort was tested for safety and efficacy versus SABA in 8000-plus patients on an as-needed treatment basis.

Miners who have worked 10 or more years are at greater risk for developing black lung disease and progressive massive fibrosis.

Under Medicaid expansion, declines in ICU admission may mean that increased access to insurance has led to improvements in clinical outcomes.

Dr Campbell wins NORD Lifetime Achievement Award and discusses key points in rare disease.

The administration of the treatment to asthma patients is fairly common, despite guidelines advocating against it under certain circumstances.

Smokers who quit had lower disease risk than the group identified as stable, low-rate smokers.

Sanofi and Regeneron reported promising results from a pair of pivotal phase 3 trials for the investigative add-on therapy.

At NORD’s 2018 Rare Impact Awards, Rare Disease Report® sat down with Estelle Benson, founder of GBS|CIDP Foundation International, to discuss what the organization is doing to fight GBS.

From food deserts to hazardous jobs that inhibit exposure and limit the means to prevent it, people of low SES are at greatest environmental health risk.

Researchers intend to follow observed infants into early childhood to gauge the vitamin's influence on pediatric asthma rates.

Children given immunocap radioallergosorbent tests when hospitalized for asthma avoided re-hopsitalization twice as long as children not given the test.

A type of flavonoid found in dark-pigmented fruits like red grapes and blueberries may slow the lung function decline that occurs with aging.

The inhaled corticosteroid from GSK is indicated for pediatric asthma patients aged 5-11 years old.

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

The monoclonal antibody reported quick and consistent exacerbation rate reduction in patients with severe eosinophilic asthma.

The once-daily, triple-drug inhaler therapy reported improvements in exacerbation rate and risk to first event.

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

Reducing use of opiates near the end of hospital stay, especially 24 hours prior to discharge, may reduce outpatient prescription of opioids.

Infants whose mothers were exposed to carbon monoxide in the second and third trimester were at highest risk for reduced lung function when they were tested at 1 month of age.

The therapy showed reduction in nighttime resting heart rate comparable to that of beta blockers.